2023 World Conference on Lung Cancer (Posters)-P2.06. Association of Clinical Response and HRQoL with Long-Term Survival with 1L Nivolumab + Ipilimumab in mNSCLC in CheckMate 227

P2.06. Association of Clinical Response and HRQoL with Long-Term Survival with 1L Nivolumab + Ipilimumab in mNSCLC in CheckMate 227 - PDF(Abstract)

Back to course

Pdf Summary

This study presented results from the CheckMate 227 trial, which evaluated the long-term effectiveness and impact on quality of life of the dual immunotherapy combination of nivolumab and ipilimumab in patients with metastatic non-small cell lung cancer (mNSCLC). The analysis included patients regardless of their tumor's programmed death ligand 1 (PD-L1) expression. <br /><br />The study found that patients who had a complete or partial tumor response at 6 months had improved long-term overall survival (OS) when treated with nivolumab plus ipilimumab compared to chemotherapy. Importantly, this OS benefit was not observed in patients with stable or progressive disease. <br /><br />In addition, the study examined the association between health-related quality of life (HRQoL) improvement and OS. Patients who experienced HRQoL improvement at 6 months, as measured by the EQ-5D-3L visual analog scale (VAS) and utility index (UI), had a greater likelihood of achieving an OS benefit with nivolumab plus ipilimumab compared to those without HRQoL improvement. This association was not observed in patients treated with chemotherapy. <br /><br />Furthermore, when HRQoL changes were evaluated over time, an improvement in EQ-5D-3L was associated with OS benefit in both the nivolumab plus ipilimumab and chemotherapy groups. <br /><br />Overall, these findings suggest that patients with a tumor response and HRQoL improvement have improved long-term survival outcomes when treated with nivolumab plus ipilimumab compared to chemotherapy. The study highlights the potential predictive value of tumor response and HRQoL improvement in identifying patients who may benefit from this dual immunotherapy regimen.

Asset Subtitle

Julie Brahmer

Meta Tag

Speaker Julie Brahmer

Topic Metastatic NSCLC: Immunotherapy - Prospective

Keywords

CheckMate 227 trial

dual immunotherapy combination

nivolumab

ipilimumab

metastatic non-small cell lung cancer

PD-L1 expression

overall survival

health-related quality of life

EQ-5D-3L

chemotherapy